Litigation Details for Journey Medical Corporation v. Padagis Israel Pharmaceuticals Ltd. (D. Del. 2022)
✉ Email this page to a colleague
Journey Medical Corporation v. Padagis Israel Pharmaceuticals Ltd. (D. Del. 2022)
| Docket | ⤷ Sign Up | Date Filed | 2022-05-02 |
| Court | District Court, D. Delaware | Date Terminated | 2022-05-19 |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | None | Referred To | |
| Parties | PADAGIS ISRAEL PHARMACEUTICALS LTD. | ||
| Patents | 10,213,512; 10,265,404; 10,322,186; 8,865,139; 8,945,516; 8,992,896; 9,675,700 | ||
| Attorneys | Nathan Roger Hoeschen | ||
| Firms | Shaw Keller LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Journey Medical Corporation v. Padagis Israel Pharmaceuticals Ltd.
Biologic Drugs cited in Journey Medical Corporation v. Padagis Israel Pharmaceuticals Ltd.
The biologic drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Journey Medical Corporation v. Padagis Israel Pharmaceuticals Ltd. (D. Del. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2022-05-02 | 1 | Complaint | (“the ʼ896 patent”); 9,675,700 (‟the ʼ700 patent”); 10,213,512 (“the ʼ512 patent”); 10,265,404 (“the …expiration of U.S. Patent Nos. 8,865,139 (“the ʼ139 patent”); 8,945,516 (“the ʼ516 patent”); 8,992,896 (“…the ʼ404 patent”); 10,322,186 (“the ʼ186 patent”); and 10,946,101 (“the ʼ101 patent”) (collectively, “the… 1. This is an action for patent infringement under the patent laws of the United States, Title…Asserted Patents. Upon information and belief, the Padagis deliberately challenged Plaintiff’s patent rights | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
